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Background: Viral infections, particularly the infections caused by herpes simplex virus (HSV), represent one of the
most serious public health concerns globally because of their devastating impact. The aim of this study was to
evaluate the antiviral potential of methanolic crude extract of an ethnomedicine Mallotus peltatus, its active fraction
and pure compound, against HSV-1 F and HSV-2 G.
Result: The cytotoxicity (CC50, the concentration of 50% cellular toxicity), antiviral effective concentration (EC50, the
concentration required to achieve 50% protection against virus-induced cytopathic effect), plaque reduction and
the selectivity index (SI, the ratio of CC50 and EC50) was determined. Results showed that the crude methanolic
extract of M. peltatus possessed weak anti-HSV activity. In contrast, the active fraction A and isolated ursolic acid
from fraction A exhibited potent antiherpesvirus activity against both HSV-1 (EC50 = 7.8 and 5.5 μg/ml; SI = 22.3 and
20) and HSV-2 (EC50 = 8.2 and 5.8 μg/ml, and SI = 21.2 and 18.97). The fraction A and isolated ursolic acid (10 μg/ml)
inhibited plaque formation of HSV-1 and HSV-2 at more than 80% levels, with a dose dependent antiviral activity,
compared to acyclovir. The time response study revealed that the anti-HSV activity of fraction A and isolated ursolic
acid is highest at 2–5 h post-infection. Moreover, the time kinetics study by indirect immunofluorescence assay
showed a characteristic pattern of small foci of single fluorescent cells in fraction A- treated virus infected cells at
2 h and 4 h post-infection, suggesting drug inhibited viral dissemination. Further, the PCR study with infected cell
cultures treated with fraction A and isolated ursolic acid at various time intervals, failed to show amplification at
48–72 h, like acyclovir treated HSV-infected cells. Moreover, fraction A or isolated ursolic acid showed no interaction
in combination with acyclovir.
Conclusion: This study revealed that bioactive fraction A and isolated ursolic acid of M. peltatus has good anti-HSV
activity, probably by inhibiting the early stage of multiplication (post-infection of 0–5 h), with SI value of 20,
suggesting its potential use as anti-HSV agents.
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Herpes simplex viruses (HSV) are a common human
pathogen that causes herpes labiles, herpes genitalis,
keratitis and encephalitis. The HSV infection caused by
type-1 (HSV-1) and type-2 (HSV-2) is mainly trans-
mitted by close personal contact, and the virus can
establishes lifelong latent infection in sensory neurons
with recurrent lesions [1]. Herpes genitalis, usually
caused by HSV-2, spread silently through sex, wreaks
enormous financial and emotional damage due to its si-
lent epidemic potential, and can cause life threatening
infection in immunocompromised people and neonates
[2]. Moreover, HSV-2 is a high risk factor for acquisi-
tion of HIV infection [3,4] and there is a synergistic re-
lationship between HIV and HSV [5-7]. A recent study
showed that HSV-suppressive therapy greatly reduced
genital and plasma HIV-1 RNA levels in co-infected
patients [8]. Hence, the risk of acquiring or transmitting
HIV infection can be greatly decreased by reducing the
spread of genital herpes.
Extensive and long term clinical use of anti-
herpesvirus agents like acyclovir, and its derivatives
ganciclovir, foscarnet results severe side effects and
drug-resistant viruses [9-11]. Further, acyclovir is
reported to incorporate into the cellular DNA, yielding
adverse drug reactions and thus, unsuitable for pregnant
women [12] and neonates [13,14]. Moreover, the major
determinants of effective immunity against HSV infec-
tion is not yet identified [15], and animal efficacy has
not predicted success in humans [16]. Furthermore, the
therapeutic vaccines failed to induce antibody-specific
responses to protect recipients from recurrences [15].
Therefore, there is an unmated and urgent need for
cheap, readily available, less toxic alternate agents to
control and prevent HSV infection and its transmission.
Ethnomedicinal plants offer a potential alternative be-
cause of their wide use in folklore medicine and some
have promising therapeutic potential [17].
One of the widely used folklore medicine Mallotus
peltatus (Geist) Muell. Arg. (Euphorbiaceae), known as
Pataque and Obottacke by Onge and Kamala by local
people, is a panatropical shrub endemic to the inland
forests of Chidiyatappu, Baratang, Jarawa Creek, and
Interview Islands of Andamans. The decoction of
M. peltatus leaves is widely used among the tribal
populations of Bay Islands, India, to treat skin and in-
testinal ailments [18], and stomachache [19]. However,
till date there is no scientific validation of the use of
this ethnomedicine. As our ongoing effort to identify
potential therapeutic lead from ethnomedicinal source
we have evaluated several ethnomedicines including
M. peltatus for antimicrobial [20], antiinflammatory and
related activities [20-22]. Based on traditional use in
skin infections the aim of the present work is toevaluate, for the first time, the in vitro antiviral activity
of the crude methanolic extract, most active fraction,
and the isolated compound(s) from the active fraction
of M. peltatus leaf.
Materials and methods
Plant materials
The leaves of M. peltatus (Geist.) Muell. Arg. was
collected from the rain forests of Middle and Southern
Andaman (Chidiyatappu, Baratang and Jaroaw Creek),
India, throughout the year. The voucher specimens were
identified by Dr. Sreekumar, Senior Scientist, Botanical
Survey of India (BSI), and deposited in the Herbarium
Section (Herbarium No. 9221) of the BSI, Andaman and
Nicobar Circle, Port Blair, for future reference. The
leaves were separately dried in shade, pulverized by a
mechanical grinder and passed through 40-mesh sieve
to get the fine powder.
Preparation of extracts
Coarsely powdered dry leaves (980 g) were extracted
with 95% methanol for 72 h at room temperature [23].
The whole extract was collected, filtered, and solvent
evaporated to dryness under reduced pressure in a Eyela
Rotary Evaporator (Japan) at 40–45°C. The concentrated
extract was aliquoted in amber-coloured bottles and
kept in dessicator for further use. The w/w yield of the
prepared extract was 8.7 ± 0.21.
Phytochemical screening and chemical isolation
The preliminary phytochemical tests of the crude
methanolic extract were done by the method of Pollock
and Stevens [24]. The concentrated crude methanolic
extracts (40 g) were partitioned between n-butanol and
water, while the aqueous part was lyophilized to dryness
(32 g) and the solvent part was removed under
reduced pressure in a rotary evaporator at 45°C. The n-
butanol fraction, weighing 35 g, was then purified on
silica gel (60–120 mesh, SRL) by column chromatog-
raphy, and eluted with petroleum ether (PE): PE: CHCl3
mixture (at different ratio) CHCl3, CHCl3: MeOH mix-
ture (at different ratios) and MeOH. All the eluted frac-
tions were monitored by thin-layer chromatography
(TLC) using pre-coated aluminium plates (E. Merck,
Germany). Two major condensed fractions A and B
were isolated along with a mixture of minor compounds
in TLC. The isolated major compound(s) were then
purified by repeated silica gel column chromatography
and were eluted by PE: CHCl3 (1:1) and CHCl3: MeOH
(95:5) mixture to get the pure compound. The spectral
analysis of isolated compounds from fraction A and B
were done by IR (JASCO-FTIR spectrophotometer in
potassium bromide discs), Mass (JEOL JMS600 Mass
Spectrometer) and NMR (Bruker DPX-300 NMR
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was also done by Co-TLC, and superimposable IR with
authentic samples. Melting points were checked in a
melting point apparatus by mixed samples, i.e. authentic
and isolated ursolic acid and β-sitosterol [20,23].
Viruses and the cell line
African green monkey kidney cells (Vero cells, ATCC,
Manassas, VA, USA) was grown and maintained in
Eagle’s minimum essential medium (EMEM), supple-
mented with 5–10% fetal bovine serum (FBS) [25]. The
standard strain HSV-2 G (ATCC-734) and HSV-1 F
(ATCC-733), purchased from the ATCC, were used.
After plaque purification, the virus was grown and the
virus stocks were stored at −80°C for future use [26],
and whenever required the virus stocks were grown on
Vero cells to determine the titers and used for further
study.
Cytotoxicity assay
Cell toxicity was monitored by determining the effect of
the methanolic crude extract, its bioactive fraction A
and isolated ursolic acid on cell morphology [27]. Vero
cells was cultured onto 96 well plate at 1.0 x105 cells/ml.
Different concentrations of methanolic crude extract/
fraction A/isolated ursolic acid and standard drug
acyclovir were added to each culture wells at a final vol-
ume of 100 μl, in triplicate, using DMSO (0.1%) as a
negative control. After incubation at 37°C with 5% CO2
for 2 days, MTT reagent (10 μl) was added to each well.
After 4 h of incubation at 37°C, the formazan was solu-
bilized by adding diluted HCl (0.04 N) in isopropanol,
and the absorbance was read at 570 nm with a reference
wavelength of 690 nm by an ELISA reader. Data were
calculated as the percentage of cell viability using the
formula: [(sample absorbance - cell free sample blank)/
mean media control absorbance)]/100%. The 50% cyto-
toxic concentration (CC50) causing visible morphological
changes in 50% of Vero cells with respect to cell control
were determined [26,28].
Antiviral assay
The antiviral activity of crude methanolic extract, frac-
tion A and the isolated ursolic acid against HSV-1 and
HSV-2 was evaluated by MTT assay [29]. Vero cells were
seeded onto 96 well plates with a concentration of 1.0
x105cells/ml. After incubation at 37°C in 5% CO2 for
6 h, the virus (0.5 MOI) was added and incubated for
1 h. Different concentrations of crude methanolic ex-
tract/fraction A/isolated ursolic acid were added to cul-
ture wells in triplicate at a final volume of 100 μl in each
well. The maximum concentration of DMSO (0.1%) was
used as negative control and acyclovir as positive control
throughout the study. After 3 days incubation at 37°C in5% CO2, the MTT test was carried out as described
above. Viral inhibition rate was calculated as: [(Atv-Acv)/
(Acd-Acv)]/100%. Atv indicates the absorbance of the
crude methanolic extract/fraction A/ursolic acid with
virus-infected cells. Acv and Acd indicate the absorbance
of the virus control and the absorbance of the cell con-
trol. The antiviral concentration of 50% effectiveness
(EC50) was defined as the concentration which achieved
50% inhibition of virus-induced cytopathic effects. The
amount of virus used in each experiment was based on
infected target cells of 0.5 MOI for both the viruses to
produce 50% MTT formazan products as in uninfected
control cells [30].
Dose–response assay
To analyze the dose-dependent effect of the test drugs
on infected Vero cells, different concentrations of frac-
tion A or isolated ursolic acid was added to HSV-1 and
HSV-2 infected Vero cell culture in triplicate. After
2–3 days MTT assay was carried out to determine
the inhibition of infection caused by the HSV, as
described previously [30,31].
Viral plaque assay
Plaque reduction assay was used to evaluate the antiviral
activity of fraction A or isolated ursolic acid and to com-
pare its activity with acyclovir. This assay evaluated the
efficacy of the test agent on inhibition of infection of
Vero cells by the free virus particles and thereby the
number of viral plaques formed in cell monolayer, as
every viral particle non-neutralized by the test agent will
infect the cells and formed a plaque. Serial dilutions of
fraction A or isolated ursolic acid in EMEM was added
to the infected cells (MOI: 0.5 of HSV-1 or HSV-2) and
incubated at room temperature, prior to the addition to
cells. After 1–2 h incubation at 37°C, the cells were
washed with fresh EMEM and overlaid with methylcellu-
lose, so the virus can spread via cell-to-cell route to form
plaques. The plaques that developed after 2–3 days of
incubation were stained with crystal violet. The effective
concentration of fraction A/isolated ursolic acid that
inhibited the number of viral plaques by 50% (EC50) was
interpolated from the dose–response curves [30,31].
Time response assay
Time response assay was used to investigate the mech-
anism of inhibition of the infection of HSV by fraction
A/isolated ursolic acid at various time periods up to
24 h. Vero cells at 1.0 x105cells/ml were grown onto 96
well plates at 37°C in 5% CO2. Following three different
approaches the virus (0.5 MOI) was exposed to the dif-
ferent concentrations of the fraction A or isolated urso-
lic acid before infecting the vero cell (pre-infection);
during infection of Vero cell (co-infection); and after the
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tion) in different time interval, in triplicate, using DMSO
(0.1%) and acyclovir as a negative and positive control
respectively. After incubation at 37°C in 5% CO2 for 2–
3 days, the MTT test was carried out as described previ-
ously [31].
Immunofluorescence (IFA) study of fraction A treated HSV
infected cells
HSV-infected Vero cells monolayer treated with differ-
ent concentrations of fraction A was washed twice with
phosphate buffered saline (PBS, pH 7.2) to remove the
cell debris. The cells were then fixed with para-
formaldehyde (4%) and blocked with 1% bovine serum
albumin (BSA) in 0.1% PBS-triton X100 solution. The
cells were washed with PBS, and then permeabilized
with 0.1% triton X100 in PBS, and incubated overnight
with FITC-labelled anti-HSV-1 mouse monoclonal anti-
bodies (Dako Cytomation, Denmark). After washing with
PBS, secondary rabbit polyclonal antibodies (Dako Cyto-
mation, Denmark) and DAPI were added, and the cells
were observed under epifluorescence microscope [32].
Amplification of viral DNA isolated from the infected cells
treated with fraction A/isolated ursolic acid by PCR
HSV-1 infected Vero cell cultures, treated with frac-
tion A/isolated ursolic acid at various time intervals
(0, 48, 72 h) were harvested. Viral DNA extracted from
the tissue culture fluid using QIAmp MiniElute Virus
Spin Kit (Qiagen GmbH, Hilden, Germany), was sub-
jected to PCR using HSV-1 type specific primers [33].
Drug- plant extracts interaction
The antiviral activity of fraction A or isolated ursolic
acid, in combination with acyclovir, was evaluated
against HSV-1 and HSV-2 (MOI 0.5) by MTT assay,
with an aim to know whether this combination can in-
crease the antiviral efficacy. The combined effect of
acyclovir and fraction A or isolated ursolic acid on HSV-
1 replication was analyzed by isobologram method [34-
36]. Here, the EC50 was used to calculate the fractional
inhibitory concentration (FIC) of the agents in combin-
ation. The interaction between fraction A or isolated
ursolic acid and acyclovir was interpreted according to
the combined FIC index [FICextract/compound + FICacyclovir]
as synergy (≤0.5), no interaction (0.5-4) or antagonism
(>4) [37].
Statistical analysis
The selective index (SI), a marker of antiviral activity,
was determined as the ratio of CC50 to EC50. The statis-
tically different effects of crude methanolic extract/
fraction A or isolated ursolic acid and acyclovir on the
inhibition of HSV were compared with the controlgroup as well as between fraction A or isolated ursolic
acid, using Student’s t-test. While the dose-dependent
effect of antiviral activity was determined by linear
regression.
Results
Spectral analysis of isolated compounds from fraction A
and fraction B
The spectral data (IR, Mass and NMR) and melting
points of isolated compounds from fraction A and
B were identical with ursolic acid and β-sitosterol,
respectively. The IR spectra of the isolated compound
from fraction A (Figure 1A) agreed well with the au-
thentic sample of ursolic acid (Figure 1B). The spectrum
showed absorption band at 3458 and 1696 cm-1 indicat-
ing the presence of hydroxyl and carboxyl groups; while
the band at 1033 and 996 cm-1 indicated –C-OH bond,
and another peak at 2929 cm-1 arises from the C-H
bonds.
The 1HNMR spectrum of the isolated compound
from fraction A in DMSO-d6, showed the signal at
11.92 indicating a –COOH group at 28th position.
While the signal at δ3.3 agrees with the presence of
–CH-OH at 3rd position, and –OH at δ4.29 peak. Signal
at δ5.12 signifies the presence of a trisubstituted double
bond (unsaturation) and the seven –CH3 groups be-
tween δ0.6 and 1.3. The shift positions of the isolated
compound were almost identical with the authentic
sample of ursolic acid (Figure 1C, 1D). The mass spectra
of the compound isolated from fraction A showed prom-
inent peak at mlz 248, and other peaks at mlz 207, 203
and 189 indicated the compound to be ursolic acid
(Figure 1E). The melting point of isolated compound is
285–287°C, similar to the authentic sample of ursolic
acid.
The IR spectrum of the isolated compound from frac-
tion B shows absorption bands at 3426 and 1056 cm-1
indicating the presence of –OH group. Other prominent
peaks were at 2935, 2852, 1706 and 1462 cm-1 arising
from the hydrocarbon skeleton. The absorption band at
965 and 802 cm-1 is due to C=C-H group (Figure 2A,
2B). The 1HNMR spectrum of the isolated compound
from fraction B shows the shift at δ3.53, indicating
CH-OH group at C3 position. The olefinic proton at
6th position has peak at δ5.34 and the six –CH3 group
appeared between δ0.6–1.03 regions. Other protons
appeared between δ1.0 - 2.3. The shift position indi-
cated that the isolated compound was almost identical
with the authentic sample of β-sitosterol (Figure 2C,
2D). The mass spectra of isolated compound had the
peak at mlz 414 (M+) with significant fragment ion
peaks at mlz 396, 382, 273 255, 231, and 213. The in-
tense peak with highest mass number at mlz 414 is
due to parent molecular ion β-sitosterol (Figure 2E). A
Figure 1 IR, 1HNMR and Mass Spectra of isolated compound from fraction A with authentic ursolic acid. The concentrated crude
methanolic extract was partitioned between n-butanol and water. The aqueous part was lyophilized while the solvent part was evaporated by
Eyela (Uni trap UT 1000, Japan) rotary evaporator at 45°C. The n-butanol fraction was purified on silica gel column, and eluted with PE: PE: CHCl3,
CHCl3: MeOH and MeOH. The eluted fractions, monitored by TLC, yielded two major condensed fractions A and B. The isolated compound(s)
from fraction A was then purified by repeated silica gel column and eluted with PE: CHCl3 (1:1) and CHCl3: MeOH (95:5) mixture to obtain pure
compound. The IR spectra of isolated compounds from fraction A done by JASCO-FTIR spectrophotometer in potassium bromide discs [A]
agreed well with the authentic sample of ursolic acid [B]. The 1HNMR spectrum of isolated compound from fraction A by Bruker DPX-300 NMR
spectrometer in DMSO-d6 solution [C] indicated that the isolated compound was almost identical with the authentic sample of ursolic acid [D].
The Mass spectra of isolated compound from fraction A, determined by JEOL JMS600 Mass Spectrometer [E] indicated the compound to be
ursolic acid.
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its lower homologue (campesterol) in small amount.
The melting point for isolated compound was 136–
137°C, similar to β-sitosterol authentic sample.
Assessment of cytotoxicity and anti-HSV activity by MTT
assay on Vero cell
The MTT assay was used to determine the toxicity of
the tested agents. The results revealed that the crude
methanolic extract of M. peltatus, its fraction A and iso-
lated ursolic acid exhibited a cytotoxic effect on Vero
cells at concentrations higher than their EC50. Results
presented in Table 1 revealed that the CC50 of crude
methanolic extract, fraction A and isolated ursolic acid
were 452 μg/ml, 174 μg/ml and 110 μg/ml respectively.
The anti-HSV activity tested by MTT assay showed thatthe crude methanolic extract, fraction A and the isolated
ursolic acid had anti-HSV activity at different dose level,
based on their EC50 value and selectivity index (SI). The
EC50 of fraction A (7.8 ± 1.6 and 8.2 ± 1.8), and isolated
ursolic acid (5.5 ± 0.54 and 5.8 ± 1.1) against HSV-1 and
HSV-2 revealed the strongest anti-HSV activity, com-
pared to the crude methanolic extract (p< 0.0001). Fur-
ther, the EC50 and SI index indicated that fraction A and
isolated ursolic acid was more active against HSV-1 than
HSV-2. On the otherhand, fraction B had CC50 and EC50
at higher concentration with very low SI index, indicat-
ing its inactiveness, compared to acyclovir (Table 1).
Dose-effect of fraction A/ursolic acid
To analyze the dose-dependent antiviral activity we
used different concentrations of fraction A, isolated
Figure 2 IR, 1HNMR and Mass Spectra of isolated compound from fraction B with authentic β-sitosterol. The concentrated crude
methanolic extract was partitioned between n-butanol and water. The aqueous part was lyophilized while the solvent part was evaporated by
Eyela (Uni trap UT 1000, Japan) rotary evaporator at 45°C. The n-butanol fraction was purified on silica gel column, and eluted with PE: PE: CHCl3,
CHCl3: MeOH and MeOH. The eluted fractions, monitored by TLC, yielded two major condensed fractions A and B. The isolated compound(s)
from fraction B was then purified by repeated silica gel column and eluted with PE: CHCl3 (1:1) and CHCl3: MeOH (95:5) mixture to obtain pure
compound. The IR spectra isolated compounds from fraction B done by JASCO-FTIR spectrophotometer in potassium bromide discs [A] agreed
well with the authentic sample of β-sitosterol [B]. The 1HNMR spectrum of isolated compound from fraction B by Bruker DPX-300 NMR
spectrometer in DMSO-d6 solution [C] indicated that the isolated compound was almost identical with the authentic sample of β-sitosterol [D].
The Mass spectra of isolated compound from fraction B, determined by JEOL JMS600 Mass Spectrometer [E] indicated the compound is β-
sitosterol.
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as positive and negative control respectively, on HSV-
1 and HSV-2 infected Vero cells. The results pre-







Crude methanolic extract 452 57.5 ± 2.45
Fraction A 174 7.8 ± 1.6
Fraction B 215 105.0 ± 5.7
Ursolic acid (isolated) 110 5.5 ± 0.54
Acyclovir 130 2.1 ± 0.1
a The 50% cytotoxic concentration for Vero cells in μg/ml.
b Concentration of compound (μg/ml) producing 50% inhibition of virus induced C
c Selectivity index (SI) = CC50/EC50.14.5 μg/ml and isolated ursolic acid at 9.0 μg/ml
exhibited nearly 100% inhibition against HSV-1. Simi-
lar effect was noticed with fraction A at15μg/ml and
isolated ursolic acid at 12.5 μg/ml against HSV-2ethanolic extract and its constituents by MTT assay









7.86 61.2 ± 3.1 7.38
22.3 8.2 ± 1.8 21.21
2.04 120.0 ± 7.2 1.79
20 5.8 ± 1.1 18.97
61.9 2.9 ± 0.1 44.8
PE of three separate experiments.
Figure 3 Dose dependent activity of isolated ursolic acid or fraction-A and acyclovir on HSV-1 [A] and HSV-2 [B]. Different
concentrations of fraction A, isolated ursolic acid or acyclovir (2.5-15 μg/ml) were added to HSV-1 and HSV-2 (black, grey and white bars) infected
Vero cells after 1 h of infection. Inhibition percentage was evaluated by MTT assay after 3 days of incubation at 37°C. Each bar represents the
mean± S.E.M of three independent experiments.
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drug concentration and inhibition rate.Assessment of plaque reduction assay
Plaque reduction assay was also used to access the anti-
viral activity of fraction A, and isolated ursolic acid,
using acyclovir and DMSO (0.1%) as positive and nega-
tive control respectively. The results revealed that both
fraction A and isolated ursolic acid at a concentrations
of 5–100 μg/ml inhibited plaque formation by HSV-1
and HSV-2, indicating their dose dependent inhibitory
activity (Figure 4). The control drug acyclovir showed
100% inhibition of plaque formation at 10 μg/ml, while
no inhibition was noticed with 0.1% DMSO (data not
shown).Time course analysis of fraction A and or isolated ursolic
acid
Time course analysis was performed with fraction A
or isolated ursolic acid to investigate the mechanismFigure 4 Plaque reduction assay of HSV-1[A] and HSV-2[B] with fracti
fraction A, isolated ursolic acid or acyclovir (5–100 μg/ml) were added to H
1-2 h incubation at 37°C the cells were overlaid with methylcellulose and t
crystal violet. The plaque number inhibition was calculated, and the effecti
number of viral plaques was interpolated from the dose–response curve.of antiviral activity. Inhibition was evaluated by MTT
assay after 3 days of infection and expressed as per-
centage inhibition. The result showed that fraction A
at 7.8 and 14.5 μg/ml inhibited HSV-1 (Figure 5A)
and HSV-2 (Figure 5B) significantly (p< 0.001) within
2–5 h post-infection, i.e., during the early period of
virus multiplication. Whereas no inhibition was found
when the virus was exposed to fraction A or isolated
ursolic acid before infection (pre-infection) or to-
gether (co-infection), upto the highest concentration
tested.Immunofluorescence (IFA) study with fraction A treated
HSV infected cells
Indirect immunofluorescence assay was used to deter-
mine the kinetics of most active fraction A on antigen
expression of HSV-1 F. The HSV-1 F infected Vero
cells were treated with different concentrations of frac-
tion A and incubated for different time intervals. The
results revealed less number of virus particle in Veroon A, isolated ursolic acid and acyclovir. Different concentrations of
SV-1 and HSV-2 (black, grey and white bars) infected Vero cells. After
he plaques developed after 2–3 days of incubation were stained with
ve concentration of fraction A/isolated ursolic acid that inhibited the
Figure 5 Inhibitory effect of fraction A during pre-infection, co-infection and post-infection on HSV-1 [A] and HSV-2 [B]. Different
concentrations of fraction A [7.8 μg/ml (square), and 14.5 μg/ml (triangle)] were added with the HSV-1 and HSV-2 infected Vero cells at various
time period like pre-infection (−1 h), co-infection (0 h) or post-infection (1-24 h). After 3 days of incubation at 37°C, inhibition was evaluated by
MTT assay and expressed as the inhibition percentage. Each bar represents the mean± S.E.M of three independent experiments.
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anti-HSV activity. The HSV antigen expression showed
a characteristic pattern of small foci of single fluores-
cent in fraction A treated HSV-1 infected cells atFigure 6 Immunofluorescence study of HSV-1 infected Vero cells trea
Cells treated with fraction A (14.5 μg/ml) for 2 h [B] and 4 h [C]; Virus cont
at 7.8 μg/ml [E], and 14.5 μg/ml [F] at 2 h post-infection; Virus Control at 4
7.8 μg/ml [H] and 14.5 μg/ml [I] at 4 h post-infection.different time interval (2-4 h post-infection), suggesting
drug inhibited viral dissemination (Figure 6). Moreover,
the antiviral activity of fraction A is more evident at
its highest concentration (14.5 μg/ml) tested.ted with fraction-A for 2–4 h post-infection. Vero cell Control [A];
rol at 2 h post-infection [D]; Virus infected cell treated with fraction A
h post-infection [G]; Virus infected cell treated with fraction A at
Figure 7 Detection of HSV-1 DNA in fraction A/ursolic acid or
acyclovir-treated and untreated cultures by PCR. Lane 1: 100 bp
Marker; Lane 2: PCR control; Lane 3: cell control; Lane 4:
cell + fraction A; Lane 5: cell + acyclovir; Lanes 6: positive control
(HSV-1 after 72 h); Lane 7: cell + HSV-1 after 48 h; Lane 8: cell + HSV-1
(MOI: 0.5) + fraction A (14.5 μg/ml); Lane 9: cell + HSV-1 (MOI:
0.5) + isolated ursolic acid (9 μg/ml); Lane 10: cell + HSV-1 (MOI:
0.5) + acyclovir (5 μg/ml).
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Vero cells treated with fraction A or isolated ursolic acid
by PCR
To compare the effect on viral replication, DNA amplifi-
cation of HSV-infected and fraction A or isolated ursolic
acid and acyclovir treated HSV-1 was detected by PCR.
The results demonstrated that the fraction A/isolated
ursolic acid treated HSV-1 (MOI 0.5) cultures at 24-72 h
duration failed to show any amplification, similar to
acyclovir (drug control) treated cultures. While HSV-1
infected culture (control) showed clear amplification of
viral DNA in 1% agarose gel at 48 h and 72 h (Figure 7).
Furthermore, in infected cells, amplification of pol gene
(internal control) indicated the integrity of the gene.
Drug- plant extracts interaction
To evaluate whether the fraction A and or isolated urso-
lic acid can able to increase the inhibitory efficacy of
acyclovir in combination, we have tested the fraction A-Table 2 Effects of fraction A/isolated ursolic acid in combinat
Fraction/Compound Mean EC50 ± SD
a
Fraction A 7.8 ± 1.6
Ursolic acid (isolated) 5.5 ± 0.54
Acyclovir alone 2.1 ± 0.1
Acyclovir + Fraction A 2.7 ± 0.15
Acyclovir + isolated ursolate 2.51 ± 0.12
a Results are the mean of three independent experiments of MTT assay.
b FICfraction/compound + FICacyclovir are FICs of fraction/compound and acyclovir, respecacyclovir and isolated ursolic acid-acyclovir combination
(synergism) by MTT assay, using isobologram method.
Our results demonstrated that the EC50 of fraction A,
isolated ursolic acid and acyclovir was 7.8, 55 and
2.1 μg/ml respectively, but in combination with acyclovir
the mean EC50 was 2.7 and 2.51 μg/ml respectively.
Moreover, the FIC index of 0.78 (between acyclovir and
fraction A) and 0.84 (between acyclovir and isolated
ursolic acid), indicated that there was no synergistic
interaction between them (Table 2). Furthermore, none
of these combinations exhibited cytotoxic effect against
Vero cell (data not shown).
Discussion
The present study for the first time, demonstrated
the anti-HSV activity of crude methanolic extract of
M. peltatus leaf, an ethnomedicine of Onge tribes of
Andaman and Nicobar Islands, India. Phytochemical
study revealed that the crude methanolic extract con-
tain two major fractions, fraction A and B, of which
fraction A had significant anti-HSV activity. Chromato-
graphic separation and spectral analysis revealed that
fraction A contains a known triterpene ursolic acid,
which possesses strong antiviral activity against HSV-1
and HSV-2 in vitro. The antiviral activity of the crude
methanolic extract was weak compared to fraction A,
probably due to its low concentrations of bioactive
compound(s). While the higher antiviral activity of frac-
tion A, than the crude methanolic extract, is due to the
higher concentration of bioactive compounds within
the fraction. Earlier study with the crude methanolic
extract of M. peltatus showed moderate antibacterial
and antifungal [20], analgesic and antiinflammatory
[20,21,38] activity. On the otherhand fraction B do not
showed any anti-HSV activity, hence not included in
further study.
The cytotoxicity study revealed that the crude metha-
nolic extract, fraction A and isolated ursolic acid had dif-
ferent CC50 due to the variable concentration of
bioactive compound(s), and the antiviral activity was
found far below the CC50 dose. Further, fraction A and
isolated ursolic acid on both HSV-1 F and HSV-2 G
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vented by the fraction A, or isolated ursolic acid with
higher SI values. However, the CC50 of fraction B was
just double the EC50, giving an insignificant SI for both
HSV-1 and HSV-2.
The dose-dependent activity and time course analysis
was done to understand how the fraction A and isolated
ursolic acid inhibit the viral infection. Interestingly, frac-
tion A and isolated ursolic acid was found to inhibit
both HSV-1 and HSV-2 infection(s) in dose-dependent
manner, with an EC50 of 7.8 μg/ml and 5.5 μg/ml for
HSV-1 F and 8.2 and 5.8 μg/ml for HSV-2 G, respect-
ively. However, 100% inhibition of HSV-1 was recorded
at 14.5 μg/ml of fraction A and 9.0 μg/ml for isolated
ursolic acid; while for HSV-2 it was 15 μg/ml of fraction
A and 12.5 μg/ml of isolated ursolic acid. Results on the
time-course effect between 0 and 5 h post-infection
revealed that the fraction A and isolated ursolic acid
possess a similar inhibitory effect. This suggests that the
mode of action is not due to inhibition of vial adsorp-
tion, but inhibition of viral replication. The time re-
sponse study, also demonstrated that both fraction A
and isolated ursolic acid probably interfere early stage of
HSV replication, as the maximum inhibition was noted
at 2-5 h post-infection. However, the real antiviral mech-
anism of fraction A and isolated ursolic acid remains to
be further elucidated.
The indirect immunofluorescence assay was carried
out to determine the kinetics of fraction A on antigen
expression of HSV-1. Maximum reduction in number of
infected fluorescent cells was observed at 4 h, along with
a characteristic pattern of small foci of positive cells and
even single fluorescent cells. This suggests that fraction
A can inhibit viral dissemination. When fraction A was
subsequently added at 2 h and 4 h time period, a signifi-
cant reduction of positive fluorescent cells was observed
(Figure 6). The non-amplification of fraction A treated
HSV-1 infected cells by PCR further complemented and
strengthened the antiviral activity of this plant. Detection
and amplification of pol gene (control gene) in fraction
A or isolated ursolic acid treated and virus infected cells
(Figure 7) indicated that there was no cytotoxicity after
treatment of cells with this plant product.
The widely used anti-herpes virus drug acyclovir is a
nucleoside analogue, specifically targets the thymidine
kinase of HSV [39]. However, its extensive and long
term use yielded drug-resistant strains [9,11], due to
mutations in viral thymidine kinase and/or DNA poly-
merase, that alter substrate sensitivity [40], and thus,
become chromosome mutagen. Moreover, efficacy of
therapeutic vaccines against primary and recurrent HSV
infection has failed [15] and thus, search for natural al-
ternative is the top priority to control and prevent HSV
infections and its transmission. The earlier reportsindicated that different species of Mallotus (M. philippi-
nensis, M. japonicus, M. repandus) contain several sec-
ondary metabolites like terpenoids (mallotucin and
malloripine), diterpenic lactones (mallotucin B,C,D), tri-
terpene alcohol (moretenol), saponins (crotoxigenin,
coroglusagenine), cardinolipids, resins (rottlerine, isorot-
tlerine), flavonoids, and β-sitosterol [41,42]. However,
there were no reports on the bioactivity and phyto-
chemistry of M. peltatus, except the isolation of ursolic
acid and β-sitosterol alongwith some fatty acids by this
group [20]. The ursolic acid is a pentacyclic amphiphilic
triterpene with planner hydroxylated polycyclic [(3b)-3-
hydroxyurs-12-en-28-oic acid] structure, ubiquitous in
medicinal plants as free acid or aglycones for triterpen-
oid saponins, and have been used since antiquity due to
multiple bioactivities [21]. Contemporary research
revealed that the ursolic acid, isolated from plants, is
cytotoxic to some tumor and cancer cells [43-45], in-
cluding skin tumor [46] and recommended for skin
cancer therapy [47]. Other studies reported its antiviral
[48], antibacterial [49], and potent anti-inflammatory
[50-52] activities. It is a highly selective inhibitor of cyc-
lic AMP-dependent protein kinase [53], human DNA
polymerases and DNA topoisomerases [54] and has
antioxidative [55] and apoptotic [56,57] activities. Urso-
lic acid isolated from Rosmarinus officinalis L. leaves is
reported to inhibit the motility of Trypanosoma cruzi
epimastigotes [58]; while ursolic acid isolated from
Ocimum sanctum, O. basilicum and O. americanum
showed anti-HSV activity with ED50 of 35–47 μg/ml by
interfering at various steps of viral multiplication [59].
Thus, our results showed that fraction A, which
contain ursolic acid as one of the compound, might
be a potential therapeutic candidate against HSV infec-
tions, as indicated by its SI value (7.86 – 22.3). Ursolic
acid is known to be less toxic, can restore skin’s colla-
gen bundle and elasticity, and is dermatologically in-
nocuous [60], while the antivirals presently used for
herpes virus treatment have high toxicity, several side
effects and problem of frequent drug resistance devel-
opment. Therefore, our study demonstrated that the
fraction A and its component(s) can serve as an alter-
native agent in herpes virus infection and thus, merit
a greater attention.
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